Phaseline

Targets › CD19

CD19 (B-lymphocyte antigen CD19): drug programs, companies and trials

269 programs from 160 companies in 557 trials: 344 Phase 1, 170 Phase 2, 37 Phase 3, 6 Phase 4; Oncology, Immunology, Neurology; next expected readout Nov 2026.

Functions as a coreceptor for the B-cell antigen receptor complex (BCR) on B-lymphocytes. Decreases the threshold for activation of downstream signaling pathways and for triggering B-cell responses to antigens. (UniProt, P15391)

Open in Phaseline: the race on CD19, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
AmgenInebilizumab
B-lymphocyte antigen CD19 binding agent
CD19Phase 4Neuromyelitis Optica Spectrum Disorder; IgG4 Related Disease; Myasthenia Gravis; Autoimmune Hepatitis …Apr 2027
Zenas BioPharma (USA)Obexelimab
B-lymphocyte antigen CD19 inhibitor; Low affinity immunoglobulin gamma Fc region receptor II-b inhibitor
CD19, FCGR2BPhase 3Warm Autoimmune Hemolytic Anemia; IgG4 Related Disease; Relapsing Multiple Sclerosis; Systemic Lupus ErythematosusDec 2026
ADC TherapeuticsLoncastuximab Tesirine
B-lymphocyte antigen CD19 binding agent
CD19Phase 3Relapsed Diffuse Large B-Cell Lymphoma; B-Cell Non-Hodgkin Lymphoma; Relapsed or Refractory Large B-cell Lymphoma; Relapsed Mantle Cell Lymphoma …Mar 2027
NovartisTisagenlecleucel (CTL019)
B-lymphocyte antigen CD19 binding agent
CD19Phase 3B-cell Acute Lymphoblastic Leukemia; Follicular Lymphoma (FL); Long Term Safety of Patients Receiving CAR-T in an Eligible Clinical Trial or Managed Access Program; B-Cell Acute Lymphoblastic Leukemia …Mar 2027
IncyteTafasitamab
B-lymphocyte antigen CD19 binding agent
CD19Phase 3Large B-Cell Lymphoma; Diffuse Large B-cell Lymphoma; Follicular Lymphoma; Hematologic Malignancies …Apr 2027
AstraZenecaAZD0120
BCMA/CD19 dual CAR T cell therapy
BCMA, CD19Phase 3Relapsed Refractory Multiple Myeloma; Newly Diagnosed Multiple Myeloma (NDMM); Newly Diagnosed Multiple Myeloma; Relapsed/Refractory Multiple Myeloma …Oct 2027
AmgenBlinatumomab
T cell surface glycoprotein CD3 cross-linking agent; B-lymphocyte antigen CD19 cross-linking agent
CD3E, CD3G, CD3D, CD19Phase 3Newly Diagnosed Philadelphia (Ph)-Negative B-cell Precursor Acute Lymphoblastic Leukemia (ALL); B Precursor Acute Lymphoblastic Leukemia; Systemic Lupus Erythematosus; B Cell Precursor Acute Lymphoblastic Leukemia …Oct 2027
AstraZenecasurovatamig (AZD0486)
Bispecific monoclonal antibody targeting CD20 and CD3E
CD19, CD3E, CD20Phase 3Large B-cell Lymphoma; Chronic Lymphocytic Leukaemia or Small Lymphocytic Lymphoma With Unmutated IGHV; Untreated Follicular Lymphoma; B-cell Non-Hodgkin Lymphoma …Jan 2028
Lyell ImmunopharmaRondecabtagene autoleucel (ronde-cel)
Dual-targeting CAR T-cell therapy targeting CD19 and CD20
CD19, CD20Phase 3Large B-cell Lymphoma; Relapsed Non-Hodgkin LymphomaDec 2028
Gilead SciencesKITE-753
Anti-CD19 CAR-T cell therapy
CD19Phase 3Relapsed or Refractory Large B-cell Lymphoma; Relapsed and/or Refractory B-cell LymphomaFeb 2030
Gilead SciencesAxicabtagene Ciloleucel
B-lymphocyte antigen CD19 binding agent
CD19Phase 3Relapsed/Refractory Follicular Lymphoma; High-risk Large B-cell Lymphoma (LBCL); Lymphoma, B-Cell; B-Cell Lymphoma Refractory …Oct 2030
Tanabe PharmaInebilizumab (MT-0551)
B-lymphocyte antigen CD19 binding agent
CD19Phase 3Systemic Sclerosis–
KK Women's and Children's HospitalAnti-CD19 CAR T-cells
CD19-directed chimeric antigen receptor (CAR) T-cell therapy
CD19Phase 2Lymphoblastic LeukemiaDec 2026
Zhejiang UniversityCD19/CD22 CAR-T cells
Bispecific CAR-T cell therapy targeting CD19 and CD22
CD19, CD22Phase 2Large B-Cell Lymphoma (LBCL); ALLDec 2026
Beijing Tongren HospitalCD19/CD22-bispecific CAR-T cells
bispecific CAR-T cell therapy targeting CD19 and CD22
CD19, CD22Phase 2B-cell Acute Lymphoblastic LeukemiaDec 2026
Juventas Cell TherapyCNCT19
anti-CD19 CAR-T cell therapy
CD19Phase 2Non-Hodgkin's Lymphoma; Relapsed or Refractory Acute Lymphoblastic Leukemia; B-cell Acute Lymphoblastic LeukemiaDec 2026
Chi Kong LiCUCART19
anti-CD19 chimeric antigen receptor modified T-cell therapy
CD19Phase 2Lymphoma, NonhodgkinDec 2026
Shanghai Ming Ju BiotechnologyRelma-cel
CD19-targeted CAR T cells
CD19Phase 2Non-Hodgkin Lymphoma; Relapsed or Refractory B-cell Lymphoma; B-cell Non Hodgkin Lymphoma; CNS Lymphoma …Dec 2026
Mitchell Cairoalpha beta depletion (α/β CD3+/CD19+ cell depletion)
Selective depletion of alpha/beta T cells and CD19+ B cells from donor stem cells for allo
CD3E, CD19Phase 2Acute LeukemiaDec 2026
Miltenyi Biomedicinezamtocabtagene autoleucel (MB-CART2019.1)
CD19-directed CAR-T cell therapy
CD19Phase 2Refractory Diffuse Large B Cell Lymphoma (DLBCL); DLBCL - Diffuse Large B Cell Lymphoma; B-Cell Neoplasm; Diffuse Large B-cell Lymphoma …Dec 2026
Liping DouCD22/CD19 CAR-T cell immunotherapy
Dual-targeted CAR-T cell therapy against CD19 and CD22
CD22, CD19Phase 2LymphomaJan 2027
Sun Yat-sen UniversityRelmacabtagene Autoleucel
Anti-CD19 CAR-T cell therapy
CD19Phase 2Large B Cell Diffuse LymphomaJan 2027
National University of Malaysiaautologous CD19 CAR-T cells
CAR-T cell therapy targeting CD19+ B cells
CD19Phase 2Relapsed B Acute Lymphoblastic Leukaemia; Systemic Lupus Erythematous (SLE)Jan 2027
City of Hope Medical CenterCD19CAR-CD28-CD3zeta-EGFRt-expressing Tn/mem-enriched T-lymphocytes
CAR-T cell expressing CD19-targeting chimeric antigen receptor with CD28 and CD3-zeta co-s
CD19Phase 2Recurrent Mantle Cell LymphomaFeb 2027
Daihong LiuCD22/CD19 CAR-T cell immunotherapy
CAR-T cell therapy targeting CD22 and CD19
CD22, CD19Phase 2LymphomaMar 2027
Kyverna TherapeuticsKYV-101
anti-CD19 chimeric antigen receptor T-cell therapy
CD19Phase 2Multiple Sclerosis, Primary Progressive; Myasthenia Gravis; Idiopathic Inflammatory MyopathiesApr 2027
Institute of Hematology & Blood Diseases Hospital, ChinaAutologous CD19-CAR T cells
anti-CD19 CAR-T cell therapy
CD19Phase 2Acute Lymphoblastic Leukemia ALL; B-cell Non-Hodgkin LymphomaApr 2027
Beijing Yongtai Ruike Biotechnology CompanyCAR-T-19 cell injection
anti-CD19 chimeric antigen receptor T cell therapy
CD19Phase 2Relapsed B-cell Acute Lymphoblastic LeukemiaApr 2027
ImmunityBioCD19 t-haNK
CAR-T cell therapy targeting CD19
CD19Phase 2Relapsed B-Cell Non Hodgkin LymphomaMay 2027
Institute of Hematology & Blood Diseases Hospital, ChinaCAR-T cells (single-target or dual-target directed against CD19, CD20, and/or CD
CAR-T cell therapy targeting CD19, CD20, and/or CD22
CD19, CD20, CD22Phase 2Relapsed or Refractory Aggressive B-cell LymphomaMay 2027
University Medical Center GroningenARI-0001
CD19-directed CAR T-cell therapy
CD19Phase 2NHLJun 2027
H. Lee Moffitt Cancer Center and Research InstituteCD19 targeted CAR T Cell Therapy
CD19-directed CAR-T cell therapy
CD19Phase 2Diffuse Large-Cell LymphomaJun 2027
Johns Hopkins All Children's HospitalTCR alpha beta T-cell and CD19 B-cell depleted haploidentical transplantation
TCR alpha beta T-cell and CD19 B-cell depleted haploidentical hematopoietic cell transplan
TCRA, TCRB, CD19Phase 2Hemoglobinopathy (Disorder); Primary Immune Deficiency DisordersJun 2027
Gilead SciencesBrexucabtagene Autoleucel (X19)
B-lymphocyte antigen CD19 binding agent
CD19Phase 2Relapsed/Refractory Mantle Cell Lymphoma; Mantle Cell Lymphoma; B-Cell Lymphoblastic Leukemia; Recurrent Mantle Cell Lymphoma …Jul 2027
Bristol-Myers SquibbCC-97540
CD19-targeted CAR T cells
CD19Phase 2Lupus Erythematosus, Systemic; Multiple Sclerosis; Systemic Lupus Erythematosus; Antineutrophil Cytoplasmic Antibody-associated VasculitisJul 2027
The First Affiliated Hospital of Soochow UniversityCD22/CD19 CAR-T cells
Dual-target CAR-T cells directed against CD22 and CD19 with 4-1BB co-stimulatory molecule
CD22, CD19Phase 2B-cell Acute Lymphoblastic LeukemiaJul 2027
Daihong LiuPolymer-Lipid Nanoparticle-Mediated Delivery of CD19/CD20 Dual-Targeting InViVoC
CAR-T cell therapy delivering dual-targeting CD19/CD20 CAR mRNA via polymer-lipid nanopart
CD19, CD20Phase 2B-cell Lymphoma RefractoryAug 2027
Chinese PLA General HospitalAnti-BCMA-CD19 CAR-T cells
Dual-target CAR-T cell therapy targeting CD19 and BCMA antigens
BCMA, CD19Phase 2IgG4 Related DiseaseSep 2027
AutolusObecabtagene Autoleucel
B-lymphocyte antigen CD19 binding agent
CD19Phase 2Lupus Nephritis; Systemic Lupus Erythematosus; Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia; Progressive Multiple Sclerosis …Sep 2027
Fate TherapeuticsFT819
allogeneic CAR-T cells targeting CD19
CD19Phase 2Lupus Nephritis; Antineutrophilic Cytoplasmic Antibody (ANCA)- Associated Vasculitis (AAV); Lymphoma, B-CellSep 2027
Allogene Therapeuticscemacabtagene ansegedleucel
allogeneic CAR T cell therapy targeting CD19
CD19Phase 2Large B-cell LymphomaDec 2027
Peking University People's HospitalBCMA-CD19 CAR-T therapy
Dual-targeted CAR-T cell therapy against BCMA and CD19
TNFRSF17, CD19Phase 2Systemic Lupus ErythematosusDec 2027
Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyCD19&CD22 bispecific CAR-T cells
Bispecific CAR-T cell therapy targeting CD19 and CD22
CD19, CD22Phase 2B-cell Acute Lymphoblastic Leukemia; B-Cell Lymphoblastic Leukemia/LymphomaDec 2027
The First Affiliated Hospital of Soochow UniversityCD19-CART
CD19-directed chimeric antigen receptor T-cell therapy
CD19Phase 2B Acute Lymphoblastic Leukemia, Philadelphia Chromosome NegativeDec 2027
iCell Gene TherapeuticsICG318
BCMA-CD19 dual-targeting CAR-T cells with IL-15/IL-15 sushi domain
TNFRSF17, CD19, BCMAPhase 2Systemic Lupus Erythematosus (SLE); Inflammatory MyopathyDec 2027
Bristol-Myers SquibbLisocabtagene Maraleucel
B-lymphocyte antigen CD19 binding agent
CD19Phase 2LymphomaJan 2028
Copenhagen University Hospital, RigshospitaletiDLI (innate donor lymphocyte infusion)
TCRαβ/CD19 depleted donor lymphocyte infusion enriched for NK cells (>10e7 cells/kg) and T
TRBC1, TRBC2, CD19Phase 2AML/MDSJan 2028
Health Institutes of TurkeyTalikabtagene Autoleucel
Anti-CD19 chimeric antigen receptor (CAR) T-cell therapy
CD19Phase 2Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia (B-ALL)Feb 2028
King Hussein Cancer CenterMB-CART19.1
CAR-T cell therapy targeting CD19
CD19Phase 2Non-Hodgkin Lymphoma Refractory/ RelapsedMar 2028
Cabaletta BioCABA-201
CD19-specific chimeric antigen receptor T cells
CD19Phase 2Idiopathic Inflammatory Myopathy; Systemic Sclerosis; Pemphigus Vulgaris; Generalized Myasthenia Gravis (gMG) …Jul 2028
Shanghai Ming Ju BiotechnologyRelmacabtagene Autoleucel (JWCAR029)
CAR-T cell therapy targeting CD19
CD19Phase 2Mantle Cell Lymphoma; Lymphoma, Large B-Cell, DiffuseAug 2028
St. Jude Children's Research HospitalChimeric antigen receptor (CAR) T cell therapy
CAR-T cell therapy targeting B-cell lineage antigen
CD19Phase 2Acute Lymphoblastic LeukemiaSep 2028
Seoul National University HospitalSNUH-CD19-CAR-T Cells
CD19-targeted chimeric antigen receptor (CAR) T-cell therapy using genetically modified au
CD19Phase 2Very High Risk Acute Lymphoblastic Leukemia; Childhood-Onset Systemic Lupus ErythematosusDec 2028
Merck & Co. (MSD)MK-1045
anti-CD19 bispecific antibody (engaging T cells for B-cell acute lymphoblastic leukemia)
CD19Phase 2Follicular Lymphoma; B-cell Acute Lymphoblastic Leukemia; Chronic Lymphocytic Leukaemia; Systemic Lupus Erythematosus …Jul 2029
Ruijin HospitalInaticabtagene autoleucel (Inati-cel; CNCT19)
CD19-targeted CAR-T cell therapy
CD19Phase 2Acute Lymphoblastic LeukemiaDec 2029
St. Jude Children's Research HospitalCD19-CAR T cell Infusion
CD19-targeted chimeric antigen receptor (CAR) T cell therapy
CD19Phase 2Acute Lymphoblastic LeukemiaMar 2030
Bristol-Myers SquibbLisocabtagene Maraleucel (JCAR017)
B-lymphocyte antigen CD19 binding agent
CD19Phase 2Lymphoma, Non-HodgkinSep 2031
John ListerChimeric Antigen Receptor (CAR) T-Cell Product (Autologous)
CAR-T cell therapy targeting CD19
CD19Phase 2B-Cell LymphomaAug 2037
National University of MalaysiaAutologous CD19-directed CAR-T cells
CD19-targeted chimeric antigen receptor T-cell therapy
CD19Phase 2Relapsed/Refractory B- Cell Non-Hodgkin Lymphoma–
Chongqing Precision BiotechAnti-CD19 UCAR-T cells
anti-CD19 CAR-T cell therapy
CD19Phase 1Dermatomyositis, JuvenileNov 2026
Gilead SciencesKITE-197
CAR-T cell therapy targeting CD19
CD19Phase 1Relapsed/Refractory Large B-cell LymphomaNov 2026
Miltenyi BiomedicineMB-CART19.1
Anti-CD19 CAR T cell therapy
CD19Phase 1Acute Lymphoblastic Leukemia Recurrent; SLE - Systemic Lupus ErythematosusNov 2026
Beijing Mabworks BiotechMBS303
T-cell bispecific antibody targeting CD19 on B cells
CD19Phase 1Non-Hodgkin's LymphomaNov 2026
Bioray LaboratoriesBRL-201
CD19-targeted CAR-T cell therapy with PD-1 site-specific integration
CD19Phase 1Non-hodgkin Lymphoma,B CellNov 2026
TG TherapeuticsAzercabtagene zapreleucel (azer-cel)
CAR-T cell therapy targeting CD19-expressing B cells
CD19Phase 1B-cell Mediated Autoimmune DisordersDec 2026
Ting Chang, MDCD19-BCMA Targeted CAR-T
Dual CD19-BCMA targeted CAR-T cell therapy
CD19, BCMAPhase 1Myasthenia GravisDec 2026
Second Affiliated Hospital, Zhejiang University, School of Medicineanti-CD19 IL10/IL15 CAR-NK
anti-CD19 chimeric antigen receptor NK cells engineered to co-express IL-10 and IL-15
CD19, IL10, IL15Phase 1B-cell Non Hodgkin LymphomaDec 2026
PersonGen BioTherapeutics (Suzhou)LV009 Injection
Anti-CD19 CAR-T cell therapy
CD19Phase 1Non-Hodgkin LymphomaDec 2026
Beijing Yongtai Ruike Biotechnology CompanyRC19D2 cell injection
anti-CD19 chimeric antigen receptor (CAR-T) cell therapy
CD19Phase 1Recurrent Diffuse Large B-Cell LymphomaDec 2026
Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyA-319
CD19xCD3 bispecific antibody (T-cell redirecting)
CD19, CD3EPhase 1Systemic Lupus ErythematosusDec 2026
University of AlbertaAnti-CD19/4-1BB/CD3ζ CAR T-cell
anti-CD19 CAR-T cell with 4-1BB and CD3ζ co-stimulatory domains
CD19Phase 1Relapsed Non Hodgkin LymphomaDec 2026
The First Affiliated Hospital of Soochow UniversityCART-138/BCMA/19/more
Multi-antigen CAR-T cell therapy targeting CD138, BCMA (TNFRSF17), CD19, and additional an
CD138, TNFRSF17, CD19Phase 1Multiple MyelomaDec 2026
Beijing GoBroad HospitalCD19 CAR-T cells
anti-CD19 chimeric antigen receptor T cells
CD19Phase 1Autoimmune Diseases; Systemic Lupus Erythematosus (SLE)Dec 2026
Ningbo No. 1 HospitalCD19-7×19 CAR-T
CD19-targeting CAR-T cells engineered to express IL-7 and CCL19
CD19Phase 1Diffuse Large B-cell LymphomaDec 2026
Baylor College of MedicineCD19.CAR/28ζ T cells
Anti-CD19 CAR-T cell therapy with CD28 costimulatory domain
CD19Phase 1Non-Hodgkin LymphomaDec 2026
University of Colorado, DenverCD19x22 CAR T Cells
Dual-targeted CAR T cell therapy against CD19 and CD22
CD19, CD22Phase 1Non-Hodgkin Lymphoma; B-cell Acute Lymphoblastic LeukemiaDec 2026
Cullinan TherapeuticsCLN-978
CD19-directed T cell engager
CD19Phase 1NHL; SLE; Rheumatoid Arthritis (RA; SjögrenDec 2026
Rong TaoKQ-2002 CAR-T cells
anti-CD19/CD22 CAR-T cell therapy
CD19, CD22Phase 1Acute Lymphoblastic Leukemia, in RelapseDec 2026
Orna TherapeuticsORN252
circular RNA encoding anti-CD19 CAR protein in lipid nanoparticle
CD19Phase 1Healthy Volunteers - Male and FemaleDec 2026
Excyte BiopharmaYK012
Bispecific antibody targeting CD19 on B cells and CD3 on T cells leading to T cell-mediate
CD19, CD3Phase 1Primary Membranous Nephropathy; B-cell Acute Lymphoblastic Leukemia; Systemic Lupus Erythematosus (SLE); Relapsed or Refractory B-Cell Non-Hodgkin LymphomaDec 2026
Second Affiliated Hospital, Zhejiang University, School of Medicineanti-CD19 CAR-NK (CB CAR-NK019)
anti-CD19 CAR-expressing cord blood-derived NK cells
CD19Phase 1B-cell Non Hodgkin LymphomaDec 2026
Memorial Sloan Kettering Cancer Centertherapeutic autologous lymphocytes
CAR-T cells genetically targeted to CD19 antigen on B cells
CD19Phase 1LeukemiaDec 2026
Essen BiotechBCMA/CD19 CAR-T cells
chimeric antigen receptor T cells targeting BCMA and/or CD19
BCMA, CD19Phase 1Autoimmune DiseasesDec 2026
Medical University of South CarolinaCD19-CD34t metabolically programmed CAR transduced T-cells
CD19-directed chimeric antigen receptor (CAR) T-cell therapy with metabolic programming an
CD19Phase 1B-cell Non Hodgkin LymphomaDec 2026
Tongji HospitalCT1190B
anti-CD19 CAR-T cell therapy
CD19Phase 1B-Cell Non-Hodgkin LymphomaDec 2026
Beijing GoBroad HospitalDonor-derived CD19 CAR T cells
CAR-T cell therapy targeting CD19
CD19Phase 1B-cell Acute Lymphoblastic LeukemiaDec 2026
The Children's Hospital of Zhejiang University School of Medicineanti-CD19-CAR-T cells
CD19-targeted CAR-T cell therapy
CD19Phase 1Systemic Lupus ErythematosusDec 2026
Chinese PLA General HospitalAllogenic CD19-targeting CAR-γδT cell
CD19-targeting CAR-γδT cell therapy with second-generation anti-CD19 CAR containing FMC63
CD19Phase 1Non Hodgkin's LymphomaDec 2026
Ohio State University Comprehensive Cancer CenterAutologous Anti-CD19/CD20/CD22 CAR T-cells
Multi-targeted CAR-T cell therapy targeting CD19, CD20, and CD22
CD19, CD20, CD22Phase 1Blast Phase Chronic Myeloid Leukemia, BCR-ABL1 PositiveDec 2026
Caribou BiosciencesCB-010
CRISPR-edited allogeneic anti-CD19 CAR-T cell therapy
CD19Phase 1Lymphoma, Non-HodgkinDec 2026
Chongqing Precision BiotechCD19 and CD22 targeted prime CAR-T cells
CAR-T cell therapy targeting CEA (CEACAM5)
CD19, CEACAM5Phase 1B-ALL; Advanced Lung Cancer; Systemic Lupus ErythematosusDec 2026
Liping DouCD22/CD19 Dual-Target CAR-T Cells
Dual-target CAR-T cell therapy targeting CD22 and CD19 antigens
CD22, CD19Phase 1B-cell Acute Lymphoblastic LeukemiaDec 2026
Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyCT1192
Dual CD19/CD20-targeting CAR-T cell therapy
CD19, CD20Phase 1Systemic Lupus Erythematosus (SLE)Dec 2026
Nanjing University School of MedicineFKC289
Dual-targeted BCMA/CD19 CAR-T cell therapy
BCMA, CD19Phase 1Lupus NephritisDec 2026
Chongqing Precision BiotechMC-1-50
CD19-targeted CAR-T cell therapy
CD19Phase 1B Cell Lymphoma; Systemic Lupus Erythematosus (SLE)Dec 2026
Peking University People's HospitalNanobody-Based CD19/CD22 Tandem Dual CAR-T
Nanobody-based dual CAR-T cells targeting CD19 and CD22
CD19, CD22Phase 1Precursor B-Cell Lymphoblastic Leukemia-LymphomaDec 2026
Pell Bio-Med TechnologyPL001
CD19-targeted chimeric antigen receptor T-cell (CAR-T)
CD19Phase 1Diffuse Large B Cell LymphomaDec 2026
The First Affiliated Hospital of Soochow UniversityRN1201 Injection
CD19 and BCMA-targeted allogeneic CAR-T cells
CD19, BCMAPhase 1Multiple Myloma; Refractory Immune-mediated Platelet Transfusion RefractorinessJan 2027
Institute of Hematology & Blood Diseases Hospital, Chinauniversal allogeneic anti-CD19/BCMA CAR T-cells
dual-targeting CAR-T cell therapy targeting CD19 and BCMA
CD19, BCMAPhase 1Autoimmune Hemolytic AnemiaJan 2027
Memorial Sloan Kettering Cancer Center19-28z chimeric receptor gene-modified T cells
Anti-CD19 CAR-T cell therapy
CD19Phase 1Leukemia; Non-Hodgkin's LymphomaJan 2027
Jiangsu Topcel-KH PharmaceuticalAnti-PD1 armored CD19 CAR-T cells
Anti-PD1 armored CD19 CAR-T cell therapy
CD19, PDCD1Phase 1Diffuse Large B Cell LymphomaJan 2027
Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyCD19/BCMA CAR-T cell therapy
Dual-targeted CAR-T cell therapy against CD19 and BCMA
CD19, BCMAPhase 1Systemic Lupus ErythematosusJan 2027
Ottawa Hospital Research InstituteCLIC-1901
anti-CD19 CAR-T cell therapy
CD19Phase 1Acute Lymphoblastic LeukemiaJan 2027
Shanghai Unicar-Therapy Bio-medicine TechnologyssCART-19
CAR-T cell therapy targeting CD19 on B-cell malignancies
CD19Phase 1B Cell LymphomaJan 2027
Gracell Biotechnologies (Shanghai)GC012F
BCMA/CD19 dual CAR-T cell therapy
TNFRSF17, CD19, BCMAPhase 1Multiple Myeloma; Refractory Systemic Lupus Erythematosus; Relapsed/Refractory AL AmyloidosisFeb 2027
Essen BiotechEB-BH2024 (CD19/CD22-CAR T cells)
CD19/CD22-targeted chimeric antigen receptor T cells
CD19, CD22Phase 1Acute Lymphoblastic Leukemia, Adult B-CellFeb 2027
University College, LondonKCAT19 T cells
Allogeneic T cells expressing chimeric antigen receptor targeting CD19
CD19Phase 1Blood CancerFeb 2027
Kali TherapeuticsKT501
Monoclonal antibody targeting CD19, BCMA and CD3 to deplete B cells and plasma cells
CD19, BCMA, CD3Phase 1Rheumatoid Arthritis (RA)Feb 2027
Bruce CreeKYV-101
CD19-targeted CAR T-cell therapy
CD19Phase 1Progressive Multiple SclerosisFeb 2027
Chinese PLA General HospitalTCR reserved and Power3 (SPPL3) gene knock-out allogeneic CD19-targeting CAR-T c
Allogeneic CAR-T cell therapy targeting CD19 with TCR alpha/beta chain (TRAC) and SPPL3 ge
TRBC, SPPL3, CD19, TCRAPhase 1Acute Lymphocytic Leukemia; Non-hodgkin LymphomaFeb 2027
Memorial Sloan Kettering Cancer Center19(T2)28z1xx TRAC CAR T cells
CD19-targeted CAR-T cell therapy with 28z costimulatory domain
CD19Phase 1B-Cell Lymphoma; Diffuse Large B Cell LymphomaFeb 2027
Medical College of WisconsinCAR-20/19-T cells
Chimeric antigen receptor T cells targeting CD20 and CD19, expanded with IL-7/IL-15
CD20, CD19Phase 1Non Hodgkin Lymphoma (NHL)Feb 2027
Chinese PLA General HospitalAllogenic CD19-CAR-γδT cell (QH103E)
CD19-targeting CAR-γδT cell therapy with gene editing for resistance to alloreactive killi
CD19Phase 1Non-hodgkin Lymphoma,B CellMar 2027
City of Hope Medical CenterAutologous CD19CAR-CD28-CD3zeta-EGFRt-expressing Tn/mem-enriched T-lymphocytes
CAR-T cell therapy targeting CD19 with CD28 costimulatory domain and EGFRt safety switch
CD19Phase 1Recurrent Diffuse Large B-Cell Lymphoma; B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classic Hodgkin LymphomaMar 2027
City of Hope Medical Centerautologous CD19CAR-CD28-CD3zeta-EGFRt-expressing Tcm-enriched T cells
CD19-directed chimeric antigen receptor (CAR) T cell with CD28 and CD3zeta costimulatory d
CD19Phase 1Recurrent Diffuse Large B-Cell Lymphoma; Adult Grade III Lymphomatoid GranulomatosisMar 2027
Beijing BiotechAutologous anti-CD19 CAR-T cells
CAR-T cell therapy targeting CD19-expressing B cells
CD19Phase 1REFRACTORY SYSTEMIC LUPUS ERYTHEMATOSUS; Scleroderma, SystemicMar 2027
ImmunityBioCD19t-haNK suspension
CAR-T cell therapy targeting CD19; engineered NK-92 cell line expressing CD19-directed CAR
CD19Phase 1Non Hodgkin's Lymphoma Refractory/RelapsedMar 2027
Memorial Sloan Kettering Cancer CenterEGFRt/19-28z/4-1BBL CAR T cells
CD19-targeting CAR T cell therapy with 28z costimulatory domain and 4-1BB ligand; EGFRt se
CD19, EGFRPhase 1Chronic Lymphocytic Leukemia (CLL)Mar 2027
GenomeFrontier Therapeutics TWGF-CART01
CD20/CD19-targeting CAR T cell therapy
CD20, CD19Phase 1Diffuse Large B Cell Lymphoma RelapsedMar 2027
University Hospital TuebingenMB-CART2219.1
CAR-T cell therapy targeting CD19 and CD22
CD19, CD22Phase 1LymphomaMar 2027
Zhujiang HospitalCD19 CAR-T cells
Anti-CD19 CAR-T cell therapy
CD19Phase 1Acute Lymphoblastic LeukemiaMar 2027
Chinese PLA General HospitalAllogeneic CD19-STAR T cell
Allogeneic T cells with TRAC locus-inserted CD19-targeting synthetic TCR, with endogenous
CD19, TRACPhase 1Non-hodgkin Lymphoma,B CellMar 2027
Hebei Senlang BiotechnologyAutologous CD19/CD22/CD20 Chimeric Antigen Receptor T-cells
Multi-target CAR-T cells targeting CD19, CD20, and CD22
CD19, CD22, CD20Phase 119 and 22+ B Cell Hematologic TumorsMar 2027
RocheEnglumafusp alfa
CD19-targeted 4-1BB ligand
CD19, TNFSF14Phase 1Lymphoma, Non-HodgkinMar 2027
Shanghai AbelZetaPrizloncabtagene autoleucel
4-1BB bispecific CAR-T cell targeting CD19 and CD20
CD19, CD20Phase 1Relapsed/Refractory Large B-Cell LymphomaMar 2027
The University of Texas Health Science Center at San AntonioLoncastuximab
Anti-CD19 antibody-drug conjugate
CD19Phase 1Diffuse Large B-cell LymphomaApr 2027
Chinese PLA General HospitalSL1617 Injection
In vivo CD19/CD20-targeted CAR T-cell immunotherapy utilizing engineered lentiviral vector
CD19, CD20Phase 1B-cell LymphomaApr 2027
Beijing GoBroad Hospitalumbilical cord blood CD19-BCMA CAR-T cells
dual-targeted CAR-T cell therapy targeting CD19 and BCMA
CD19, BCMA, CD5, CD7Phase 1Refractory Lupus Nephritis; T-Cell Non-Hodgkin LymphomaApr 2027
iCell Gene TherapeuticsBCMA-CD19 cCAR T cells
Dual-targeted CAR T cell therapy targeting BCMA and CD19 expressed on B cells and plasma c
BCMA, CD19Phase 1Multiple Myeloma in Relapse; Refractory Immune CytopeniaApr 2027
Stanford UniversityKYV-101 anti-CD19 CAR-T cell therapy
anti-CD19 CAR-T cell therapy
CD19Phase 1Dermatomyositis; Multiple SclerosisApr 2027
NkartaNKX019
CD19-directed CAR NK cell therapy
CD19Phase 1Lupus Nephritis; Systemic Sclerosis; Lymphoma, Non-HodgkinApr 2027
TherornaTI-0032-III injection
Lipid nanoparticle-formulated circular RNA encoding CD19 chimeric antigen receptor (CAR)
CD19Phase 1Systemic Lupus Erythematosus (SLE)May 2027
Ruijin HospitalABO2203
mRNA encoding CD19/CD3 T cell engager
CD19, CD3EPhase 1B-cell Non-Hodgkin LymphomaMay 2027
University of California, DavisCD19 Chimeric Antigen Receptor T Cells
CD19-targeted CAR-T cell therapy
CD19Phase 1Recurrent Diffuse Large B-Cell LymphomaMay 2027
Memorial Sloan Kettering Cancer Centermodified T cells
CD19-targeted CAR-T cell therapy
CD19Phase 1Relapsed B-Cell Acute Lymphoblastic LeukemiaMay 2027
Beijing GoBroad HospitalDual-targeting BCMA-CD19 CAR-T cell
Dual-target CAR-T cell therapy targeting BCMA and CD19
BCMA, CD19Phase 1Relapsed or Refractory Multiple Myeloma (RRMM)May 2027
Chinese PLA General HospitalCAR19TIF cells
BCOR and ZC3H12 genes knock-out CD19-targeting CAR-T cells
CD19Phase 1Acute Lymphocytic Leukemia; B Cell LymphomaMay 2027
The First Affiliated Hospital of Xiamen UniversityGB5005 chimeric antigen receptor T-cell injection
anti-CD19 CAR-T cell therapy
CD19Phase 1Non-hodgkin LymphomaMay 2027
ImugeneAzer-cel (PBCAR0191)
Allogeneic anti-CD19 CAR-T cell therapy
CD19Phase 1Non-Hodgkin LymphomaJun 2027
Vironexis BiotherapeuticsVNX-101
Adeno-associated viral vector encoding CD3/CD19 bi-specific T-cell engager
CD3, CD19Phase 1B-cell Acute Lymphoblastic LeukemiaJun 2027
City of Hope Medical CenterCD19CAR-CD28-CD3zeta-EGFRt-expressing Tcm-enriched T-lymphocytes
CAR-T cell therapy targeting CD19 with CD28 and CD3zeta signaling domains, EGFRt transgene
CD19Phase 1B Acute Lymphoblastic LeukemiaJun 2027
Second Affiliated Hospital, Zhejiang University, School of Medicine7x19 CAR-T
anti-CD19 CAR-T cell therapy
CD19Phase 1Primary Mediastinal B-cell Lymphoma (PMBCL)Jun 2027
Second Affiliated Hospital, Zhejiang University, School of MedicineCD19-CAR novel oncolytic vaccinia virus (RGV005)
anti-CD19 CAR-NK cells derived from cord blood
CD19Phase 1Primary Mediastinal B-cell Lymphoma (PMBCL); Refractory/Relapsed B-cell LymphomaJun 2027
Bambino Gesù Hospital and Research InstituteCD19-CAR_Lenti_ALLO
allogeneic CD19-directed chimeric antigen receptor T cell therapy
CD19Phase 1B-cell Acute Lymphoblastic LeukemiaJun 2027
The First Affiliated Hospital with Nanjing Medical UniversityCD19/CD20 Dual-Target in vivo CAR-T Lentiviral product
Dual-target CAR-T cell therapy targeting CD19 and CD20
CD19, CD20Phase 1Relapsed/Refractory B-cell MalignanciesJun 2027
University of Colorado, DenverUCD19 CAR T cells
anti-CD19 chimeric antigen receptor-expressing (CAR) T cells
CD19Phase 1Acute Lymphoid LeukemiaJun 2027
Sumithira VasuAnti-CD19/CD20/CD22 CAR T-Cells
Multi-targeted CAR-T cell therapy targeting CD19, CD20, and CD22
CD19, CD20, CD22Phase 1Recurrent Acute Lymphoblastic LeukemiaJul 2027
St. Jude Children's Research HospitalCD19-CAR(Mem) T-cells
Allogeneic CD19-CAR.CD45RA-negative T-cells with 41BBz costimulatory domain
CD19Phase 1Acute Lymphoblastic Leukemia, in RelapseJul 2027
National Cancer Institute (NCI)CD19/CD22-CAR-transduced T cells
bicistronic CAR-T cell therapy targeting CD19 and CD22
CD19, CD22Phase 1B-NHLJul 2027
University of UtahAnti-CD19 CAR-T cells
anti-CD19 chimeric antigen receptor T cells (CAR-T)
CD19Phase 1Acute Lymphoblastic LeukemiaJul 2027
King Faisal Specialist Hospital & Research CenterCD19 CAR T cells
chimeric antigen receptor T cells targeting CD19
CD19Phase 1Relapsed Refractory Acute Lymphoblastic LeukemiaJul 2027
The First Affiliated Hospital of Air Force Medical UniversityCD19 CAR-T cell therapy
CD19-directed chimeric antigen receptor T-cell therapy
CD19Phase 1Refractory Membranous NephropathyJul 2027
Chongqing Precision BiotechCD19-targeted CAR-T
CAR-T cell therapy targeting CD19
CD19Phase 1Juvenile DermatomyositisJul 2027
Marcela V. Maus, M.D.,Ph.D.CD79b-19 CAR T cells
CAR-T cells targeting CD79b and CD19
CD79B, CD19Phase 1Non-hodgkin LymphomaAug 2027
The First Affiliated Hospital of Soochow UniversityCD19-targeted CAR T-cell therapy
CAR-T cell therapy targeting CD19
CD19Phase 1Acute Lymphoblastic Leukemia With Failed RemissionAug 2027
Fondazione Matilde Tettamanti Menotti De Marchi OnlusCARCIK-CD19
Allogeneic cytokine-induced killer cells transduced with CD19 chimeric antigen receptor (C
CD19Phase 1B-cell NHLSep 2027
CytoCaresCC312
anti-CD19 monoclonal antibody
CD19Phase 1Non-hodgkin Lymphoma; SLE - Systemic Lupus ErythematosusSep 2027
Vinmec Research Institute of Stem Cell and Gene TechnologyAutologous CD19-Targeted CAR-T Cells
CD19-targeted CAR-T cell therapy
CD19Phase 1Refractory Systemic Lupus ErythematosusSep 2027
Iksuda TherapeuticsIKS03
anti-CD19 antibody-drug conjugate with pyrrolobenzodiazepine cytotoxic payload
CD19Phase 1B-cell Non-Hodgkin LymphomaSep 2027
Memorial Sloan Kettering Cancer CenterIn Vitro Expanded Allogeneic Epstein-Barr Virus Specific Cytotoxic T-Lymphocytes
Allogeneic EBV-specific T cells genetically modified to express CAR targeting CD19
CD19, EBNA1, EBNA2, EBNA3Phase 1Acute Lymphocytic LeukemiaSep 2027
Stephan Grupp MD PhDAutologous Humanized CD19-Directed Chimeric Antigen Receptor T-Cells (huCART19)
CD19-directed CAR-T cell therapy
CD19Phase 1B Cell Acute Lymphoblastic Leukemia (B-ALL); B-cell Acute Lymphoblastic LeukemiaSep 2027
City of Hope Medical CenterAutologous Anti-CD19 CAR-expressing T Lymphocytes
anti-CD19 chimeric antigen receptor (CAR) T-cell therapy
CD19Phase 1B Acute Lymphoblastic LeukemiaSep 2027
The Children's Hospital of Zhejiang University School of MedicineCD19 Universal CAR-T cells
anti-CD19 CAR-T cell therapy
CD19Phase 1Systemic Lupus ErythematosusSep 2027
Hinge BioHB2198
Tetravalent bispecific anti-CD19/CD20 antibody with dual Fc domains
CD19, CD20Phase 1Healthy Volunteer; Systemic Lupus Erthematosus (SLE)Oct 2027
Bangdong GongiC9/CAR19/IL15 CB-NK cell
Chimeric Antigen Receptor Natural Killer Cell targeting CD19 with inducible suicide gene (
TNFRSF9, CD19, IL15Phase 1Primary Sjogren's SyndromeOct 2027
Bristol-Myers SquibbLisocabtagene Maraleucel (JCAR017)
B-lymphocyte antigen CD19 binding agent
CD19Phase 1Leukemia, Lymphocytic, Chronic, B-Cell; Recurrent Transformed Chronic Lymphocytic Leukemia; Lymphoma; Refractory Aggressive B-cell Lymphomas …Nov 2027
Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyCD19 CAR-T cell infusion
CD19-targeted CAR-T cell therapy
CD19Phase 1Systemic Lupus ErythematosusDec 2027
Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyCD19 Universal CAR-γδT Cells
Anti-CD19 CAR-γδT cell therapy
CD19Phase 1Systemic Lupus ErythematosusDec 2027
Paul SzabolcsCD3/CD19 negative hematopoietic stem cells
Negatively selected hematopoietic stem cells depleted of CD3+ and CD19+ cells
CD3, CD19Phase 1Idiopathic Pulmonary FibrosisDec 2027
Kali TherapeuticsKT502
Monoclonal antibody targeting CD19 and CD3 for B cell depletion
CD19, CD3Phase 1Rheumatoid Arthritis (RA)Dec 2027
Beijing GoBroad HospitalOL-CD19-GDT
CD19-targeting genetically modified T cell therapy
CD19Phase 1Systemic Sclerosis (SSc)Dec 2027
Shenzhen University General HospitalCD19/CD20 CAR/TRuC-T
Dual-targeted CAR/TRuC T-cell therapy against CD19 and CD20
CD19, CD20Phase 1Relapsed/Refractory B-cell LymphomaDec 2027
Guangzhou Women and Children's Medical CenterCD19/CD22 CAR-T cell therapy
Dual-target CAR-T cell therapy targeting CD19 and CD22 using retroviral vector-based tande
CD19, CD22Phase 1Acute Lymphoblastic LeukemiaDec 2027
Tongji HospitalUniversal CD19 CAR-γδT Cell Injection (QH103)
Allogeneic CD19 CAR-γδT cell therapy
CD19Phase 1Multiple Sclerosis (MS)Dec 2027
Grit BiotechnologyGT719 Injection
anti-CD19 CAR-T cell therapy
CD19Phase 1Neurological Autoimmune Diseases; Hematological Malignancy (Leukemia- Lymphoma)Jan 2028
Aibin Liang,MD,Ph.D.dualCAR-NK19/70 cell
anti-CD19/CD70 CAR-NK cell therapy
CD19, CD70Phase 1Refractory or Relapsed B-cell Non-Hodgkin LymphomaJan 2028
SanofiSAR448501/DR-0201
Bispecific antibody targeting CD19 and CD3E
CD19, CD3EPhase 1B-cell Non Hodgkin Lymphoma; Systemic Lupus Erythematosus (SLE)Jan 2028
TICAROSTC011
Anti-CD19 chimeric antigen receptor T cell therapy
CD19Phase 1Relapsed Large B-cell LymphomaFeb 2028
Allogene TherapeuticsALLO-329
Allogeneic dual CAR T-cell therapy targeting CD19 and CD70
CD19, CD70Phase 1Systemic Lupus Erythematosus (With and Without Nephritis)Feb 2028
Institute of Hematology & Blood Diseases Hospital, ChinaUCAR T-cell
universal allogeneic anti-CD19/BCMA CAR T-cells
CD19, BCMAPhase 1Systemic Lupus ErythematosusFeb 2028
Memorial Sloan Kettering Cancer Center19-28z/IL-18 CAR T cells
CAR-T cell therapy targeting CD19 with IL-18 co-expression
CD19, IL18Phase 1Philadelphia-Negative ALLFeb 2028
City of Hope Medical CenterAnti-CD19-CAR CMV-specific T-lymphocytes
CMV-specific CD19 CAR-T cells
CD19Phase 1B-Cell Non-Hodgkin Lymphoma; High Grade B-Cell Non-Hodgkin's LymphomaMar 2028
Mayo ClinicAutologous Anti-CD19 CAR-expressing T-lymphocytes IC19/1563
CD19-directed CAR-T cell therapy
CD19Phase 1Recurrent B-Cell Non-Hodgkin LymphomaMar 2028
Ruijin HospitalAnti-CD19/CD22 Dual-Target Cord Blood CAR-T Cells
Dual-targeted CAR-T cells expressing chimeric antigen receptors against CD19 and CD22
CD19, CD22Phase 1B-cell Acute Lymphoblastic LeukemiaMar 2028
TriArm Therapeutics (Taiwan)ARM011
CD19-targeted CAR-T cell therapy
CD19Phase 1Acute Lymphoblastic LeukemiaApr 2028
Chongqing Precision BiotechPTOC1
CD19-targeted CAR-T cell therapy
CD19Phase 1Systemic Lupus ErythematosusApr 2028
Nelson HamerschlakChimeric antigen receptor T cells
Anti-CD19 CAR-T cell therapy
CD19Phase 1Acute Lymphoblastic Leukemia, in RelapseMay 2028
City of Hope Medical CenterCD19CAR-CD28-CD3zeta-EGFRt-expressing Tn/mem T-lymphocytes
CD19-CAR T cell therapy with CD28 and CD3zeta costimulatory domains and truncated EGFR saf
CD19Phase 1Central Nervous System LymphomaMay 2028
Tianjin Medical University Cancer Institute and HospitalLUCAR-G39D
Dual-targeted CAR-T cell therapy targeting CD19 and CD20
CD19, CD20Phase 1B-Cell Non-Hodgkin Lymphoma-RecurrentJun 2028
Xi'an No.3 Hospitalallogeneic cord blood-derived, dual-targeting CD19/BCMA CAR-T cells (UCAR-T)
dual-targeting CD19/BCMA CAR-T cell therapy
CD19, BCMAPhase 1Relapsed/Refractory Multiple Myeloma(MM)Jul 2028
Paul SzabolcsCD3/CD19 depleted leukocytes
Negative selection depleting CD3+ and CD19+ T cells and B cells from donor bone marrow via
CD3E, CD19Phase 1Sickle Cell AnemiaAug 2028
Tanabe PharmaLoncastuximab Tesirine (MT-2111)
B-lymphocyte antigen CD19 binding agent
CD19Phase 1Diffuse Large B-Cell LymphomaAug 2028
Memorial Sloan Kettering Cancer CenterMB-CART19.1
CD19-directed CAR-T cell therapy
CD19Phase 1Primary Central Nervous System (CNS) LymphomaAug 2028
Chulalongkorn UniversityCMD63
CD19-targeted CAR-T cell with IL-7Rα signaling domain
CD19, IL7RPhase 1Relapse B Acute Lymphoblastic LeukemiaSep 2028
UCARsgen Biotech LimitedCT1190B
CAR-T cell therapy targeting CD19
CD19Phase 1Large B-Cell Lymphoma (LBCL)Sep 2028
Peking University Cancer Hospital & InstituteLUCAR-20SP
CD19-directed CAR-T cell therapy
CD19Phase 1Relapsed B-cell Non-Hodgkin LymphomaSep 2028
Institut de Recherches Internationales ServierUCART19
allogeneic CAR-T cell therapy targeting CD19
CD19Phase 1Advanced Lymphoid LeukemiaSep 2028
Seattle Children's HospitalSCRI-CAR19v3
CD19-targeting CAR-T cell therapy
CD19Phase 1Systemic Lupus ErythematosusOct 2028
Chinese PLA General HospitalBEX101 injection
anti-CD19 CAR-T cell therapy
CD19Phase 1Non-Hodgkin's LymphomaOct 2028
National University Hospital, SingaporeEpo-R-CD19 CAR T
CAR-T cell therapy targeting CD19 and Epo-R expressing B cell lymphoma cells
ERBB2, CD19Phase 1B-cell Lymphoma RefractoryOct 2028
Antengene BiologicsATG-201
Bispecific T-cell engager (TCE) binding CD3 and CD19
CD3, CD19Phase 1Systemic Lupus ErythematosusDec 2028
Myeloid TherapeuticsCRT-402
CD19-targeted CAR-T cell therapy designed to deplete CD19-positive B cells
CD19Phase 1Autoimmune DiseasesDec 2028
Chinese PLA General HospitalKSVCBD injection
in vivo CAR-T therapy targeting CD19 and BCMA
CD19, BCMAPhase 1Multiple Myeloma; Non-Hodgkin's LymphomaDec 2028
The Children's Hospital of Zhejiang University School of MedicineUCAR T-cell
Universal allogeneic anti-CD19/BCMA CAR T-cells
CD19, BCMAPhase 1Autoimmune DiseasesDec 2028
National Institute of Allergy and Infectious Diseases (NIAID)huCART19
Humanized Chimeric Antigen Receptor T cell targeting CD-19
CD19Phase 1Kidney TransplantDec 2028
National Cancer Institute (NCI)Anti-CD19 and anti-CD20 bicistronic CAR T cells
bicistronic CAR T cells targeting CD19 and CD20
CD19, CD20Phase 1Chronic Lymphocytic LeukemiaDec 2028
TCRx Therapeutics Co.LtdKSV01 Injection
CD19-targeted CAR-T cell therapy using lentiviral vector
CD19Phase 1Non-Hodgkin Lymphoma; B-ALLDec 2028
Institute of Hematology & Blood Diseases Hospital, ChinaQT-019C
universal allogeneic anti-CD19/BCMA CAR T-cells
CD19, BCMAPhase 1SLE - Systemic Lupus ErythematosusJan 2029
Abramson Cancer Center at Penn Medicineanti-CD19 CAR-T
CAR-T cell therapy targeting CD19
CD19Phase 1Large B Cell LymphomaJan 2029
Allogene TherapeuticsALLO-501A
Anti-CD19 allogeneic CAR T cell therapy
CD19Phase 1Relapsed or Refractory Large B Cell Lymphoma, Relapsed or Refractory Chronic Lymphocytic Leukemia, Relapsed or Refractory Small Lymphocytic LymphomaFeb 2029
Bristol-Myers SquibbBMS-986515
CD19-targeted allogeneic CAR T cell therapy
CD19Phase 1Refractory Autoimmune DiseasesMar 2029
Poseida TherapeuticsP-CD19CD20-ALLO1
Allogeneic CAR-T cells targeting CD19 and CD20
CD19, CD20Phase 1Diffuse Large B-Cell Lymphoma, Not Otherwise SpecifiedMar 2029
Umoja BiopharmaUB-VV111
CD19 CAR T cell therapy generated in vivo via gene therapy
CD19Phase 1Lymphoma, B-CellMar 2029
University College, LondonBCMA/CD19 CAR T cells
CAR T cells co-expressing BCMA and CD19 CARs
BCMA, CD19Phase 1Multiple MyelomaMar 2029
Shenzhen University General HospitalCD19-CAR.p40-T
CD19-targeted CAR-T cell expressing autocrine IL-40
CD19Phase 1B Cell LymphomaApr 2029
AvenCell TherapeuticsAllo-QuadCAR01-T
Allogeneic CAR-T cell therapy targeting CD19/CD20
CD19, CD20Phase 1Lymphoma Diffuse Large B-cellApr 2029
Shanghai Exuma BiotechnologyC402-CD19-CAR
Anti-CD19 CAR-T cell therapy
CD19Phase 1Diffuse Large B-cell-lymphomaApr 2029
University of Texas Southwestern Medical CenterCAR-T cell therapy
CD19-directed chimeric antigen receptor T-cell therapy
CD19Phase 1Non Hodgkin LymphomaMay 2029
Gilead SciencesKITE-363
CAR-T cell therapy targeting CD19
CD19Phase 1Chronic Inflammatory Demyelinating Polyneuropathy; Relapsed and/or Refractory B-cell LymphomaJun 2029
National Cancer Institute (NCI)Autologous HuCD19 (Anti-CD19) CAR T cells
Anti-CD19 chimeric antigen receptor T-cell immunotherapy
CD19Phase 1Leukemia, Lymphocytic, Chronic, B-CellJul 2029
University Hospital, Lilleautologous anti-CD19 CAR-T cells
anti-CD19 CAR-T cell therapy
CD19Phase 1Relapsed Adult AMLJul 2029
Baylor College of MedicineCD19CAR-28-zeta T cells
CD19-targeted chimeric antigen receptor (CAR) T cell therapy with CD28 costimulatory domai
CD19Phase 1B Cell LymphomaJul 2029
Instituto de Investigación Biomédica de SalamancaTranspoCART19
Anti-CD19 CAR-T cell therapy
CD19Phase 1Refractory B-Cell LymphomaJul 2029
Department of Hematology,Rheumatology and Immunology,Pu'er People's HospitalGN001
CD19-targeted CAR T cell therapy delivered via lentiviral vector
CD19Phase 1Relapsed or Refractory B-Cell Non-Hodgkin LymphomaAug 2029
Second Affiliated Hospital, Zhejiang University, School of Medicine7×19-THEMIS CAR-T cells
IL7 and CCL19-armed anti-CD19 CAR-T cell therapy with Themis coexpression
CD19Phase 1Relapsed/Refractory Large B-cell Lymphoma (LBCL)Sep 2029
Instituto de Investigación Sanitaria de la Fundación Jiménez DíazTranspoCART19
CD19-directed CAR-T cell therapy
CD19Phase 1Lupus NephritisSep 2029
Seattle Children's HospitalAutologous CD19 CAR+ EGFTt + T cells
CD19-directed CAR-T cell therapy with EGFRt safety tag
CD19Phase 1B Cell LeukemiaJan 2030
St. Jude Children's Research HospitalCD19-CD22 CAR T cell
bispecific CAR T cell targeting CD19 and CD22
CD19, CD22Phase 1Acute Lymphoblastic LeukemiaJan 2030
CRISPR TherapeuticsCTX112 (Zugocabtagene geleucel, zugo-cel)
CD19-directed CAR-T cell therapy; allogeneic T cells genetically modified using CRISPR-Cas
CD19Phase 1B-cell Lymphoma; Warm Autoimmune Hemolytic Anemia (WAIHA)Jan 2030
Children's Hospital of PhiladelphiaCART19
Anti-CD19 chimeric antigen receptor T cell expressing scFv:41-BB:TCRζ
CD19Phase 1SLEFeb 2030
University of Colorado, DenverCD19CAR-CD3Zeta-4-1BB-Expressing Autologous T-Lymphocyte Cells
CD19-directed CAR-T cell therapy with 4-1BB costimulatory domain
CD19Phase 1B-cell Acute Lymphoblastic LeukemiaMar 2030
AbClonAT101
Anti-CD19 chimeric antigen receptor (CAR) T-cell therapy
CD19Phase 1B-cell Non Hodgkin LymphomaMar 2030
Arovella TherapeuticsALA-101
anti-CD19 CAR-T cell therapy
CD19Phase 1Non Hodgkin Lymphoma (NHL)Mar 2030
Instituto de Investigación Hospital Universitario La PazAutologous CD19/CD22 CAR T cells
Anti-CD19/CD22 chimeric antigen receptor T cell therapy
CD19, CD22Phase 1Precursor Cell Lymphoblastic Leukemia-LymphomaJun 2030
CurocellCRC01
anti-CD19 CAR-T cell therapy
CD19Phase 1Relapsed Large B-cell LymphomaAug 2030
National Cancer Institute (NCI)mCD19-CAR-CD28-CD3-zeta (anti-CD19 CAR)
anti-CD19 CAR-T cell therapy with CD28 and CD3-zeta costimulatory domains
CD19Phase 1Hematologic MalignanciesNov 2030
Baylor College of MedicineCD19.CAR-CD28Z T Cells
CAR-T cells targeting CD19 with CD28 costimulatory domain
CD19Phase 1Non-Hodgkin's LymphomaDec 2030
Baylor College of MedicineCD19CAR/virus specific T cells
chimeric antigen receptor (CAR) T cells targeting CD19
CD19Phase 1Acute Lymphoblastic Leukemia (ALL)Apr 2031
St. Jude Children's Research HospitalCD45RA-depleted CD19-CAR T cells
CD19-directed chimeric antigen receptor T cell therapy
CD19Phase 1Relapsed Pediatric ALLDec 2031
CRISPR TherapeuticsCTX112
CD19-directed allogeneic T-cell therapy with CRISPR-Cas9 gene editing
CD19Phase 1SLE (Systemic Lupus)Dec 2031
RocheP-CD19CD20-ALLO1
allogeneic CAR-T cell therapy targeting CD19 and CD20
CD19, CD20Phase 1Multiple SclerosisAug 2032
University College, LondonCD19CAR T-cells
anti-CD19 CAR-T cell therapy
CD19Phase 1Primary CNS LymphomaDec 2032
Loyola UniversityCD19-CD34 CAR transduced T cells
CAR-T cells targeting CD19 expressed on B cell malignancies
CD19Phase 1B-Cell Acute Lymphoblastic Leukemia, AdultDec 2034
Seattle Children's HospitalPatient-derived CD19- and CD22 specific CAR T-cells
Dual-specificity CAR-T cells targeting CD19 and CD22
CD19, CD22Phase 1LeukemiaMar 2035
Takara BioTBI-1501
anti-CD19 chimeric antigen receptor (CAR)-T cell therapy
CD19Phase 1Lymphoblastic Leukemia, Acute AdultMar 2035
Stanford UniversityCD19/CD22 Chimeric Antigen Receptor T-Cell Therapy
CAR T cell therapy targeting CD19 and CD22
CD19, CD22Phase 1B Acute Lymphoblastic LeukemiaAug 2035
Benjamin TomlinsonAnti-CD19 Chimeric Antigen Receptor T Cells
CAR-T cells targeting CD19
CD19Phase 1Non-Hodgkin LymphomaFeb 2036
Seattle Children's HospitalPatient Derived CD19 specific CAR T cells with EGFRt
CD19-directed CAR-T cell therapy with 4-1BB costimulatory domain and truncated EGFR marker
CD19Phase 1CD19+ Acute LeukemiaJul 2036
Seattle Children's HospitalSCRI-huCAR19v1
CD19-specific CAR T cell therapy with fully human binding domain, 4-1BB-ζ costimulatory do
CD19Phase 1LeukemiaDec 2036
Seattle Children's HospitalSCRI-huCAR19v2
CD19-specific CAR T cell therapy with fully human binding domain, 4-1BB-ζ costimulatory do
CD19Phase 1LeukemiaDec 2036
UNC Lineberger Comprehensive Cancer CenteriC9-CAR19 T cells
Anti-CD19 chimeric antigen receptor (CAR) T cells with inducible caspase 9 safety switch
CD19Phase 1Acute Lymphoblastic Leukemia; LymphomaSep 2037
Baylor College of MedicineCD19.CAR-aNKT cells
CD19-targeted chimeric antigen receptor (CAR) allogeneic natural killer T (NKT) cells
CD19Phase 1Refractory B-Cell Non-Hodgkin LymphomaMay 2040
Seattle Children's Hospitalsecond generation 4-1BBζ EGFR806-EGFRt
Dual-targeting CAR-T cell therapy against EGFR and CD19 with 4-1BB costimulation
EGFR, CD19Phase 1Pediatric Solid TumorJun 2040
The First Affiliated Hospital of Soochow UniversityssCART-19 cells combined with CD19+ feeding T cells (FTCs)
CD19-directed CAR-T cell therapy combined with CD19+ engineered T cells to enhance CAR-T e
CD19Phase 1Acute Lymphoblastic Leukemia, Adult B-CellJul 2040
Benjamin TomlinsonFully human anti-CD19 CAR-T cells
Anti-CD19 chimeric antigen receptor T cell therapy
CD19Phase 1Non Hodgkin LymphomaDec 2040
Seattle Children's Hospitalsecond generation 4-1BBζ B7H3-EGFRt-DHFR
Dual-targeted CAR T cell therapy directed at B7H3 and CD19 with 4-1BB costimulatory domain
B7H3, CD19Phase 1Pediatric Solid TumorDec 2040
Melody SmithAllogeneic donor-derived CD19/CD22-CAR T cells
bivalent CAR-T cell therapy targeting CD19 and CD22
CD19, CD22Phase 1Lymphoid LeukemiaDec 2045
Chinese PLA General HospitalATHENA CAR-T (TRAC and Power3 (SPPL3) Genes Knock-out Allogeneic CD19-targeting
Anti-CD19 CAR-T cell therapy with TRAC and SPPL3 gene knockout in allogeneic T cells
CD19Phase 1Non Hodgkin's Lymphoma–
Vitebsk Regional Clinical Cancer CentreAnti-CD19 CAR T-cell therapy
anti-CD19 CAR-T cell therapy
CD19Phase 1Chronic Lymphocytic Leukaemia (CLL)–
Institute of Hematology and Blood Transfusion, Czech RepublicAutologous CAR19 T lymphocytes
CAR-T cell therapy targeting CD19
CD19Phase 1Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia–
Fondazione Policlinico Universitario Agostino Gemelli IRCCSCD19-CAR_Lenti
anti-CD19 CAR T-cell therapy
CD19Phase 1Lupus Erythematosus, Systemic–
Shenzhen University General HospitalCD19/CD20-CAR.p40-T
Dual-targeting CD19/CD20 chimeric antigen receptor T cell therapy
CD19, CD20Phase 1Relapsed/Refractory B-cell Lymphoma–
Institute of Hematology & Blood Diseases Hospital, ChinaCNCT19
Second-generation CAR-T cell therapy targeting CD19 with 4-1BB/CD3-ζ costimulatory domain
CD19Phase 1Autoimmune Hemolytic Anemia–
Zhejiang UniversityCNCT19
anti-CD19 CAR-T cell therapy
CD19Phase 1Advanced Hepatocellular Carcinoma–
Han weidongDecitabine-primed Tandem CAR19/20 engineered T cells
Tandem CAR-T cell therapy targeting CD19 and CD20, primed with decitabine
CD19, CD20Phase 1Relapsed and Refractory B-cell Non-Hodgkin's Lymphoma–
David WaldUF-KURE19 CAR-T cells
CAR-T cells with scFV targeting CD19
CD19Phase 1Non Hodgkin Lymphoma–
Changhai Hospitalanti-CD19 CAR NK cells
anti-CD19 chimeric antigen receptor (CAR) NK cell therapy
CD19Phase 1Autoimmune Diseases–
Miltenyi Biomedicineanti-CD19 CAR T cell therapy
anti-CD19 CAR-T cell therapy
CD19Phase 1Systemic Lupus Erythematosus; Relapse/Refractory B-cell Acute Lymphoblastic Leukemia; Systemic Lupus Erthematosus–
C. Babis Andreadisanti-CD19 CAR-T cells
CD19-directed chimeric antigen receptor T-cell therapy
CD19Phase 1Refractory Non-Hodgkin Lymphoma–

Conditions

Acute Lymphoblastic Leukemia (26) B-cell Acute Lymphoblastic Leukemia (22) Systemic Lupus Erythematosus (21) B Acute Lymphoblastic Leukemia (12) Non-Hodgkin Lymphoma (10) Lymphoma (10) B-cell Non Hodgkin Lymphoma (8) Systemic Lupus Erythematosus (SLE) (8) Large B-cell Lymphoma (8) B Cell Lymphoma (7) Recurrent Diffuse Large B-Cell Lymphoma (7) Leukemia (7)

Modalities

other (112), mixed (77), protein or peptide (42), small molecule (25), antibody (7)

Companies

Chinese PLA General Hospital (10) Memorial Sloan Kettering Cancer Center (8) Seattle Children's Hospital (8) City of Hope Medical Center (7) Institute of Hematology & Blood Diseases Hospital, China (6) The First Affiliated Hospital of Soochow University (6) Union Hospital, Tongji Medical College, Huazhong University of Science and Technology (6) Second Affiliated Hospital, Zhejiang University, School of Medicine (5) Gilead Sciences (5) Beijing GoBroad Hospital (5) Baylor College of Medicine (5) Bristol-Myers Squibb (5) Chongqing Precision Biotech (5) St. Jude Children's Research Hospital (5) National Cancer Institute (NCI) (4) University College, London (3) Ruijin Hospital (3) Allogene Therapeutics (3) University of Colorado, Denver (3) Shenzhen University General Hospital (3)

Related targets

CD22 (24) CD20 (22) BCMA (20) CD3E (7) CD3 (6) TNFRSF17 (4) IL15 (2) CD70 (2) TCRA (2) EGFR (2) IL10 (1) PDCD1 (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.